Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Sponsor
Halozyme Therapeutics (Industry)
Overall Status
Completed
CT.gov ID
NCT00774800
Collaborator
(none)
22
1
1
5
4.4

Study Details

Study Description

Brief Summary

Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with both Humalog and Humulin-R in order to determine if it improves the absorption of these insulins to more closely mimic the body's natural increase in insulin in response to a meal.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Participants received all 4 interventions in the same order.

Dose-finding visits were conducted to identify the appropriate dose of Humalog and Humulin-R. For each Humalog dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). For each Humulin-R dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humulin-R, corresponding to a mass concentration of 20.0 μg/mL rHuPH20 (at final concentration of 100 U/mL of Humulin-R).

Study Design

Study Type:
Interventional
Actual Enrollment :
22 participants
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humulin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients
Study Start Date :
Oct 1, 2008
Actual Primary Completion Date :
Mar 1, 2009
Actual Study Completion Date :
Mar 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R

Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified. Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal. Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified. Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal. Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL. All dose finding visits and interventions were separated by 3-10 days.

Drug: Humalog
Other Names:
  • Insulin lispro
  • Drug: Humulin-R
    Other Names:
  • Humulin
  • Recombinant human insulin
  • Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
    Other Names:
  • HYLENEX
  • PH20
  • Other: Liquid meal
    Other Names:
  • Ensure
  • Outcome Measures

    Primary Outcome Measures

    1. Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60) [Predose up to 60 minutes postdose]

      AUC was derived as the area under the serum insulin concentration profile from 0 to time "t." Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; and at 20, 30, 45, and 60 mins postdose.

    Secondary Outcome Measures

    1. Maximum Serum Insulin Concentration (Cmax) [Predose up to 480 minutes postdose]

      Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.

    2. Time to Maximum Serum Insulin Concentration (Tmax) [Predose up to 480 minutes postdose]

      Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.

    3. Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG]) [Predose up to 4 hours after injection of study drug]

      AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 140 milligrams per deciliter (mg/dL) within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before; at 3, 6, 9, 12, 15, 20, 25 minutes; and every 10 minutes from minute 30 to 240 postdose.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male or female of age 18 to 65 years, inclusive. Females of child-bearing potential must use a standard and effective means of birth control for the duration of the study.

    • Participants with Type 1 diabetes mellitus treated with insulin for greater than or equal to 12 months.

    • Body mass index (BMI) 18.0 to 29.0 kilograms per meter squared (kg/m^2), inclusive.

    • Glycosylated hemoglobin A1c (HbA1c) less than or equal to 10% based on local laboratory results.

    • Fasting C-peptide less than 0.6 nanograms per milliliter (ng/mL).

    • Current treatment with insulin less than 1.2 units per kilogram per day (U/kg/day).

    • Participants should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug injections and assessments required in this protocol.

    Exclusion Criteria:
    • Known or suspected allergy to any component of any of the study drugs in this trial.

    • Previous enrollment in this trial.

    • A participant who has proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.

    • Clinically significant (as judged by the Investigator) active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on electrocardiogram [ECG]), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure greater than or equal to 100 millimeters of mercury [mmHg] and/or systolic blood pressure greater than or equal to 160 mmHg after 5 minutes in the supine position).

    • History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the participant.

    • Clinically significant findings (as judged by the Investigator) in routine laboratory data, including anemia with hemoglobin less than lower limits of normal at screening.

    • Use of drugs which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia.

    • Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator.

    • Current addiction to alcohol or substances of abuse as determined by the Investigator.

    • Blood donation (>500 milliliters [mL]) within the 9 weeks prior to first day of dosing on study.

    • Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives or barrier methods).

    • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation.

    • Symptomatic gastroparesis.

    • History or evidence of use of any tobacco- or nicotine-containing product within 6 months of screening or screening quantitative urine nicotine concentration >50 ng/mL.

    • Receipt of any investigational drug within 4 weeks of first day of dosing in this study.

    • Any condition (intrinsic or extrinsic) that in the judgment of the Investigator will interfere with trial participation or evaluation of data.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Profil Institute for Clinical Research, Inc. Chula Vista California United States 91911

    Sponsors and Collaborators

    • Halozyme Therapeutics

    Investigators

    • Principal Investigator: Linda A Morrow, M.D., Profil Institute for Clinical Research, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Halozyme Therapeutics
    ClinicalTrials.gov Identifier:
    NCT00774800
    Other Study ID Numbers:
    • HZ2-08-05
    • HALO-117-201
    First Posted:
    Oct 17, 2008
    Last Update Posted:
    Feb 26, 2019
    Last Verified:
    Feb 1, 2019

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title First Humalog+PH20, Then Humalog, Humulin-R+PH20, Humulin-R
    Arm/Group Description Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified. Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal. Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified. Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal. Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL. All dose finding visits and interventions were separated by 3-10 days.
    Period Title: Intervention 1
    STARTED 22
    Received at Least One Dose of Study Drug 22
    COMPLETED 22
    NOT COMPLETED 0
    Period Title: Intervention 1
    STARTED 22
    COMPLETED 22
    NOT COMPLETED 0
    Period Title: Intervention 1
    STARTED 22
    Received at Least One Dose of Study Drug 22
    COMPLETED 22
    NOT COMPLETED 0
    Period Title: Intervention 1
    STARTED 22
    COMPLETED 22
    NOT COMPLETED 0
    Period Title: Intervention 1
    STARTED 22
    Received at Least One Dose of Study Drug 22
    COMPLETED 22
    NOT COMPLETED 0
    Period Title: Intervention 1
    STARTED 22
    COMPLETED 22
    NOT COMPLETED 0
    Period Title: Intervention 1
    STARTED 22
    Received at Least One Dose of Study Drug 21
    COMPLETED 21
    NOT COMPLETED 1

    Baseline Characteristics

    Arm/Group Title Overall Study
    Arm/Group Description Humalog+recombinant human hyaluronidase PH20 (rHuPH20): Up to 3 dose-finding (DF) visits (each visit separated by 3-10 days [d]) until an appropriate dose of Humalog was identified. For each DF visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously (SC) per unit of Humalog, corresponding to a mass concentration (conc) of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final conc of 91 U/mL of Humalog) Humalog alone: After a 3-10 d washout (wo), a single SC injection of the appropriate identified dose of Humalog was delivered Humulin-R+rHuPH20: After a 3-10 d wo, up to 2 DF visits (both visits separated by 3-10 d) until an appropriate dose of Humulin-R was identified. For each DF visit, a total of 24 U of rHuPH20 was injected SC per unit of Humulin-R, corresponding to a mass conc of 20.0 μg/mL rHuPH20 (at final conc of 100 U/mL of Humulin-R) Humulin-R alone: After a 3-10 d wo, a single SC injection of the appropriate identified dose of Humulin-R was delivered
    Overall Participants 22
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    40.7
    (10.73)
    Sex: Female, Male (Count of Participants)
    Female
    7
    31.8%
    Male
    15
    68.2%
    Ethnicity (NIH/OMB) (Count of Participants)
    Hispanic or Latino
    4
    18.2%
    Not Hispanic or Latino
    18
    81.8%
    Unknown or Not Reported
    0
    0%
    Race (NIH/OMB) (Count of Participants)
    American Indian or Alaska Native
    0
    0%
    Asian
    1
    4.5%
    Native Hawaiian or Other Pacific Islander
    0
    0%
    Black or African American
    2
    9.1%
    White
    19
    86.4%
    More than one race
    0
    0%
    Unknown or Not Reported
    0
    0%
    Region of Enrollment (participants) [Number]
    United States
    22
    100%

    Outcome Measures

    1. Primary Outcome
    Title Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)
    Description AUC was derived as the area under the serum insulin concentration profile from 0 to time "t." Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; and at 20, 30, 45, and 60 mins postdose.
    Time Frame Predose up to 60 minutes postdose

    Outcome Measure Data

    Analysis Population Description
    Participants who received at least one dose of Humalog alone, Humalog + rHuPH20, Humulin-R + rHuPH20, or Humulin-R alone with evaluable AUC0-60 data.
    Arm/Group Title Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Arm/Group Description Humalog + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 3 dose-finding visits (each visit was separated by 3-10 days) until an appropriate dose of Humalog was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humalog was delivered before a liquid meal. After a 3-10 day washout, Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 2 dose-finding visits (both visits were separated by 3-10 days) until an appropriate dose of Humulin-R was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humulin-R, corresponding to a mass concentration of 20.0 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 100 U/mL of Humulin-R). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humulin-R was delivered before a liquid meal.
    Measure Participants 21 21 17 17
    Mean (Standard Deviation) [nanomole*minute per liter (nmol*min/L)]
    12346.67
    (4996.79)
    8297.62
    (3670.03)
    11607.65
    (6770.61)
    4331.76
    (3068.10)
    Statistical Analysis 1
    Statistical Analysis Overview Comparison Group Selection Humalog + rHuPH20, Humalog Alone
    Comments Due to the exploratory nature of this study, the sample size is not based on a formal calculation.
    Type of Statistical Test Superiority or Other
    Comments
    Statistical Test of Hypothesis p-Value 0.0011
    Comments Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.
    Method ANOVA
    Comments
    Method of Estimation Estimation Parameter Geometric Least Squares Means Ratio
    Estimated Value 1.54
    Confidence Interval () %
    to
    Parameter Dispersion Type:
    Value:
    Estimation Comments
    Statistical Analysis 2
    Statistical Analysis Overview Comparison Group Selection Humulin-R + rHuPH20, Humulin-R Alone
    Comments Due to the exploratory nature of this study, the sample size is not based on a formal calculation.
    Type of Statistical Test Superiority or Other
    Comments
    Statistical Test of Hypothesis p-Value <0.0001
    Comments Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.
    Method ANOVA
    Comments
    Method of Estimation Estimation Parameter Geometric Least Squares Means Ratio
    Estimated Value 3.06
    Confidence Interval () %
    to
    Parameter Dispersion Type:
    Value:
    Estimation Comments
    2. Secondary Outcome
    Title Maximum Serum Insulin Concentration (Cmax)
    Description Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
    Time Frame Predose up to 480 minutes postdose

    Outcome Measure Data

    Analysis Population Description
    Participants who received at least one dose of Humalog alone, Humalog + rHuPH20, Humulin-R + rHuPH20, or Humulin-R alone with evaluable Cmax data
    Arm/Group Title Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Arm/Group Description Humalog + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 3 dose-finding visits (each visit was separated by 3-10 days) until an appropriate dose of Humalog was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humalog was delivered before a liquid meal. After a 3-10 day washout, Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 2 dose-finding visits (both visits were separated by 3-10 days) until an appropriate dose of Humulin-R was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humulin-R, corresponding to a mass concentration of 20.0 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 100 U/mL of Humulin-R). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humulin-R was delivered before a liquid meal.
    Measure Participants 21 21 17 17
    Mean (Standard Deviation) [Picomoles per liter (pmol/L)]
    307.67
    (125.73)
    226.38
    (85.51)
    285.88
    (139.54)
    165.05
    (68.98)
    Statistical Analysis 1
    Statistical Analysis Overview Comparison Group Selection Humalog + rHuPH20, Humalog Alone
    Comments Due to the exploratory nature of this study, the sample size is not based on a formal calculation.
    Type of Statistical Test Superiority or Other
    Comments
    Statistical Test of Hypothesis p-Value 0.0057
    Comments Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.
    Method ANOVA
    Comments
    Method of Estimation Estimation Parameter Geometric Least Squares Means Ratio
    Estimated Value 1.35
    Confidence Interval () %
    to
    Parameter Dispersion Type:
    Value:
    Estimation Comments
    Statistical Analysis 2
    Statistical Analysis Overview Comparison Group Selection Humulin-R + rHuPH20, Humulin-R Alone
    Comments Due to the exploratory nature of this study, the sample size is not based on a formal calculation.
    Type of Statistical Test Superiority or Other
    Comments
    Statistical Test of Hypothesis p-Value <0.0001
    Comments Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.
    Method ANOVA
    Comments
    Method of Estimation Estimation Parameter Geometric Least Squares Means Ratio
    Estimated Value 1.66
    Confidence Interval () %
    to
    Parameter Dispersion Type:
    Value:
    Estimation Comments
    3. Secondary Outcome
    Title Time to Maximum Serum Insulin Concentration (Tmax)
    Description Tmax was determined as the timepoint where the maximum of all valid concentration measurements for each measurement series was observed. Samples were taken 30, 20, and 10 minutes (mins) prior to treatment; every 3 mins from mins 0 through 15; at 20, 30, and 45 mins; every 30 mins from mins 60 through 240; and every 60 minutes from mins 300 through 480 postdose.
    Time Frame Predose up to 480 minutes postdose

    Outcome Measure Data

    Analysis Population Description
    Participants who received at least one dose of Humalog alone, Humalog + rHuPH20, Humulin-R + rHuPH20, or Humulin-R alone with evaluable tmax data.
    Arm/Group Title Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Arm/Group Description Humalog + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 3 dose-finding visits (each visit was separated by 3-10 days) until an appropriate dose of Humalog was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humalog was delivered before a liquid meal. After a 3-10 day washout, Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 2 dose-finding visits (both visits were separated by 3-10 days) until an appropriate dose of Humulin-R was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humulin-R, corresponding to a mass concentration of 20.0 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 100 U/mL of Humulin-R). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humulin-R was delivered before a liquid meal.
    Measure Participants 21 21 17 17
    Mean (Standard Deviation) [minutes]
    30.24
    (8.73)
    48.57
    (13.34)
    57.06
    (30.83)
    116.76
    (65.02)
    Statistical Analysis 1
    Statistical Analysis Overview Comparison Group Selection Humalog + rHuPH20, Humalog Alone
    Comments Due to the exploratory nature of this study, the sample size is not based on a formal calculation.
    Type of Statistical Test Superiority or Other
    Comments
    Statistical Test of Hypothesis p-Value <0.0001
    Comments Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.
    Method ANOVA
    Comments
    Method of Estimation Estimation Parameter Least Squares Means Difference
    Estimated Value -18.33
    Confidence Interval () %
    to
    Parameter Dispersion Type:
    Value:
    Estimation Comments
    Statistical Analysis 2
    Statistical Analysis Overview Comparison Group Selection Humulin-R + rHuPH20, Humulin-R Alone
    Comments Due to the exploratory nature of this study, the sample size is not based on a formal calculation.
    Type of Statistical Test Superiority or Other
    Comments
    Statistical Test of Hypothesis p-Value 0.0018
    Comments
    Method ANOVA
    Comments Statistical testing was considered exploratory, with no adjustment for inflation of Type 1 error due to multiplicity of testing.
    Method of Estimation Estimation Parameter Least Squares Means Difference
    Estimated Value -62.46
    Confidence Interval () %
    to
    Parameter Dispersion Type:
    Value:
    Estimation Comments
    4. Secondary Outcome
    Title Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG])
    Description AUC(BG) values are reported for participants whose blood glucose (BG) was elevated higher than 140 milligrams per deciliter (mg/dL) within 4 hours of consuming a liquid meal. Blood samples were collected at 30, 20, 10, and within 5 minutes before; at 3, 6, 9, 12, 15, 20, 25 minutes; and every 10 minutes from minute 30 to 240 postdose.
    Time Frame Predose up to 4 hours after injection of study drug

    Outcome Measure Data

    Analysis Population Description
    Participants who received at least one dose of Humalog alone, Humalog + rHuPH20, Humulin-R + rHuPH20, or Humulin-R alone with evaluable AUC(BG) data.
    Arm/Group Title Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Arm/Group Description Humalog + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 3 dose-finding visits (each visit was separated by 3-10 days) until an appropriate dose of Humalog was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humalog was delivered before a liquid meal. After a 3-10 day washout, Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 2 dose-finding visits (both visits were separated by 3-10 days) until an appropriate dose of Humulin-R was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humulin-R, corresponding to a mass concentration of 20.0 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 100 U/mL of Humulin-R). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humulin-R was delivered before a liquid meal.
    Measure Participants 22 22 21 21
    Geometric Mean (90% Confidence Interval) [minutes*milligrams per deciliter]
    111
    526
    181
    1,238

    Adverse Events

    Time Frame Adverse event data collected from Day 1 through to the end of the study, for up to 80 days.
    Adverse Event Reporting Description
    Arm/Group Title Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Arm/Group Description Humalog + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 3 dose-finding visits (each visit was separated by 3-10 days) until an appropriate dose of Humalog was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humalog, corresponding to a mass concentration of 18.2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humalog was delivered before a liquid meal. After a 3-10 day washout, Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20) was delivered for up to 2 dose-finding visits (both visits were separated by 3-10 days) until an appropriate dose of Humulin-R was identified. For each dose-finding visit, a total of 24 units (U) of rHuPH20 was injected subcutaneously per unit of Humulin-R, corresponding to a mass concentration of 20.0 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 100 U/mL of Humulin-R). After a 3-10 day washout, a single subcutaneous injection of the appropriate identified dose of Humulin-R was delivered before a liquid meal.
    All Cause Mortality
    Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total / (NaN) / (NaN) / (NaN) / (NaN)
    Serious Adverse Events
    Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/22 (0%) 0/22 (0%) 0/22 (0%) 0/21 (0%)
    Other (Not Including Serious) Adverse Events
    Humalog + rHuPH20 Humalog Alone Humulin-R + rHuPH20 Humulin-R Alone
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 14/22 (63.6%) 15/22 (68.2%) 18/22 (81.8%) 18/21 (85.7%)
    Gastrointestinal disorders
    Nausea 0/22 (0%) 0 1/22 (4.5%) 1 0/22 (0%) 0 0/21 (0%) 0
    Vomiting 0/22 (0%) 0 1/22 (4.5%) 1 1/22 (4.5%) 1 0/21 (0%) 0
    General disorders
    Injection site erythema 0/22 (0%) 0 0/22 (0%) 0 2/22 (9.1%) 2 0/21 (0%) 0
    Infections and infestations
    Upper respiratory tract infection 0/22 (0%) 0 1/22 (4.5%) 1 0/22 (0%) 0 0/21 (0%) 0
    Viral infection 0/22 (0%) 0 0/22 (0%) 0 0/22 (0%) 0 1/21 (4.8%) 1
    Injury, poisoning and procedural complications
    Contusion 1/22 (4.5%) 1 0/22 (0%) 0 1/22 (4.5%) 1 0/21 (0%) 0
    Joint sprain 0/22 (0%) 0 0/22 (0%) 0 0/22 (0%) 0 1/21 (4.8%) 1
    Investigations
    Blood glucose decreased 13/22 (59.1%) 33 11/22 (50%) 17 14/22 (63.6%) 39 14/21 (66.7%) 25
    Metabolism and nutrition disorders
    Hypoglycaemia 5/22 (22.7%) 6 4/22 (18.2%) 6 9/22 (40.9%) 13 7/21 (33.3%) 9
    Musculoskeletal and connective tissue disorders
    Musculoskeletal pain 0/22 (0%) 0 0/22 (0%) 0 1/22 (4.5%) 1 1/21 (4.8%) 1
    Nervous system disorders
    Headache 1/22 (4.5%) 1 3/22 (13.6%) 3 3/22 (13.6%) 3 1/21 (4.8%) 1
    Skin and subcutaneous tissue disorders
    Ecchymosis 0/22 (0%) 0 0/22 (0%) 0 1/22 (4.5%) 2 0/21 (0%) 0
    Hyperhidrosis 0/22 (0%) 0 0/22 (0%) 0 1/22 (4.5%) 1 0/21 (0%) 0

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    All information obtained as a result of this study or during the conduct of this study will be regarded as confidential. The Investigator agrees to use the information for the purpose of carrying out this study and for no other purpose, unless prior written permission from the Sponsor (Halozyme) is obtained.

    Results Point of Contact

    Name/Title Vice President, Endocrinology Clinical Development
    Organization Halozyme Therapeutics, Inc.
    Phone (858) 794-8889
    Email
    Responsible Party:
    Halozyme Therapeutics
    ClinicalTrials.gov Identifier:
    NCT00774800
    Other Study ID Numbers:
    • HZ2-08-05
    • HALO-117-201
    First Posted:
    Oct 17, 2008
    Last Update Posted:
    Feb 26, 2019
    Last Verified:
    Feb 1, 2019